CTL’s enzyme-linked immunospot (ELISPOT) assays are effective readout systems for cytokine-based immune monitoring and standardisation strategies.
ELISPOT assays and the related multiplex FluoroSpot technology are ideal for measurement of per-cell antigen-specific cytokine production and direct ex-vivo cytotoxicity assays.
T-cell functional avidity studies and epitope mapping, and B-cell ELISPOT assays for determining the class or subclass of antibody-secreting cells, are just a few areas where ELISPOT and FluoroSpot are used.
Reference laboratory for ELISPOT
CTL has been chosen repeatedly to serve as a reference laboratory for ELISPOT, including the Immune Tolerance Network and the Sabin Vaccine Institute’s Cancer Vaccine Consortium.
CTL has also been awarded multiple indefinite delivery/indefinite quantity (IDIQ) contracts by the US National Institute of Health (NIH) for development and validation of human and animal models of infectious diseases, as well as for biodefense applications.
In addition, CTL has optimised, qualified, and validated test methods for its clients in various test systems, including human, mouse, non-human primates and pig. This experience has provided the company a wealth of expertise encompassing a wide range of assay types, from ELISPOT, to FluoroSpot, ELISA, multiplex cytokine bead arrays (CBA), flow cytometry for cell phenotyping and multimer readouts, and BrdU proliferation assays in both regulated and non-regulated studies.
Analysis of antigen-specific B-cell antibody production
CTL has recently developed novel ELISPOT and FluoroSpot assays for the analysis of antigen-specific B-cell antibody production. It is now able to detect and analyse each IgG subclass produced by stimulated B-cells simultaneously in the same assay well.
Likewise, combinations of up to four antibody classes can be detected simultaneously, enabling large-scale, high-throughput screening providing a wealth of data using a fraction of the cell material.
CTL Laboratories has onsite facilities for processing whole blood, peripheral blood mononuclear cell (PBMC) separation, and cryo-preservation of lymphocytes for subsequent functional assay testing. This allows it to act as a central processing facility for multisite studies. The company is also fully-equipped to handle the logistics of collection, processing, cataloguing, and cryo-storage of samples from multiple clinical collection sites.
Click here for more information.